This report offers an evaluation of Merck-Wellcome Trust Hilleman Laboratories (Hilleman Laboratories or the labs), a public private venture launched in 2009 by the Wellcome Trust and Merck & Co., Inc. (Merck), intended to contribute to the development of high-impact, affordable vaccines for people in developing countries. As a starting point, this report offers context on the global burden of infectious disease, borne disproportionately by people living in the developing world, and discusses related challenges in developing, deploying, and financing vaccines to address this burden.
Read the full article by viewing the PDF below.
Please wait while flipbook is loading. For more related info, FAQs and issues please refer to DearFlip WordPress Flipbook Plugin Help documentation.